Financials in USD. Standardized financial statements.
A compact view of how Biocept, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Revenue? | $25.86M | $61.25M | $27.46M | $5.53M |
| Revenue Growth? | -57.8% | +123.0% | +396.7% | 0.0% |
| Cost of Revenue? | $28.44M | $37.76M | $21.34M | $10.98M |
| Gross Profit? | -$2.58M | $23.48M | $6.12M | -$5.45M |
| Gross Margin? | -10.0% | +38.3% | +22.3% | -98.6% |
| Operating Expenses? | $29.40M | $25.89M | $21.59M | $17.61M |
| Operating Income? | -$31.98M | -$2.41M | -$15.47M | -$23.06M |
| EBITDA? | -$30.24M | -$879,000 | -$16.57M | -$24.11M |
| Income Before Tax | -$32.21M | -$2.70M | -$17.81M | -$25.14M |
| Income Tax Expense | -$125,000 | $125,000 | $0 | $0 |
| Net Income? | -$32.09M | -$2.82M | -$17.81M | -$25.14M |
| EPS? | $-56.78 | $-5.73 | $-45.10 | $-365.01 |
| Diluted EPS? | $-56.78 | $-5.73 | $-45.10 | $-365.01 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality